Siemens Medical Solutions announced that it has been granted an Investigational New Drug (IND) Exemption by the FDA to conduct a Phase I clinical trial of (F-18) 3′-fluoro-3′-deoxythymidine (FLT), a molecular imaging biomarker that has shown promise in monitoring the proliferation of cancer cells, which could help physicians quickly determine the effectiveness of cancer therapies.
Read MoreU.S. researchers on Monday unveiled a computerized prosthetic ankle and foot that could change the lives of a growing number of amputees returning from battle in Iraq and Afghanistan.
Read MoreThe two teams of researchers who pioneered in discovering the accelerating expansion of the universethe Supernova Cosmology Project and the High-Z Supernova Search Teamhave both been awarded for their efforts.
Read MoreSiemens has signed a merger agreement with Dade Behring Inc that would have Siemens acquiring all outstanding shares of Dade Behring by submitting a cash offer to the Dade Behring shareholders of $77 per common share.
Read MoreModern imaging technology may help us take a look at the face of a woman immortalized in stone who hasnt walked the earth for thousands of years.
Read More